Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada, K1H 8L6.
JAMA. 2010 Nov 17;304(19):2145-53. doi: 10.1001/jama.2010.1665.
Studies from Australia and the United Kingdom have shown that some patients with cystic fibrosis are infected with common transmissible strains of Pseudomonas aeruginosa.
To determine the prevalence and incidence of infection with transmissible strains of P. aeruginosa and whether presence of the organism was associated with adverse clinical outcomes in Canada.
DESIGN, SETTING, AND PARTICIPANTS: Prospective observational cohort study of adult patients cared for at cystic fibrosis clinics in Ontario, Canada, with enrollment from September 2005 to September 2008. Sputum was collected at baseline, 3 months, and yearly thereafter for 3 years; and retrieved P. aeruginosa isolates were genotyped. Vital status (death or lung transplant) was assessed for all enrolled patients until December 31, 2009.
Incidence and prevalence of P. aeruginosa isolation, rates of decline in lung function, and time to death or lung transplantation.
Of the 446 patients with cystic fibrosis studied, 102 were discovered to be infected with 1 of 2 common transmissible strains of P. aeruginosa at study entry. Sixty-seven patients were infected with strain A (15%), 32 were infected with strain B (7%), and 3 were simultaneously infected with both strains (0.6%). Strain A was found to be genetically identical to the Liverpool epidemic strain but strain B has not been previously described as an epidemic strain. The incidence rate of new infections with these 2 transmissible strains was relatively low (7.0 per 1000 person-years; 95% confidence interval [CI], 1.8-12.2 per 1000 person-years). Compared with patients infected with unique strains of P. aeruginosa, patients infected with the Liverpool epidemic strain (strain A) and strain B had similar declines in lung function (difference in decline in percent predicted forced expiratory volume in the first second of expiration of 0.64% per year [95% CI, -1.52% to 2.80% per year] and 1.66% per year [95% CI, -1.00% to 4.30%], respectively). However, the 3-year rate of death or lung transplantation was greater in those infected with the Liverpool epidemic strain (18.6%) compared with those infected with unique strains (8.7%) (adjusted hazard ratio, 3.26 [95% CI, 1.41 to 7.54]; P = .01).
A common strain of P. aeruginosa (Liverpool epidemic strain/strain A) infects patients with cystic fibrosis in Canada and the United Kingdom. Infection with this strain in adult Canadian patients with cystic fibrosis was associated with a greater risk of death or lung transplantation.
来自澳大利亚和英国的研究表明,一些囊性纤维化患者感染了常见的可传播铜绿假单胞菌菌株。
确定加拿大可传播铜绿假单胞菌菌株感染的患病率和发病率,以及该生物体的存在是否与不良临床结局有关。
设计、地点和参与者:前瞻性观察队列研究,纳入了安大略省囊性纤维化诊所的成年患者,招募时间为 2005 年 9 月至 2008 年 9 月。在基线、3 个月和此后每年采集痰液 3 年;并对分离的铜绿假单胞菌进行基因分型。所有入组患者的生存状态(死亡或肺移植)均进行评估,直至 2009 年 12 月 31 日。
铜绿假单胞菌分离的发生率和患病率、肺功能下降率以及死亡或肺移植时间。
在 446 例囊性纤维化患者中,102 例在研究开始时发现感染了 2 种常见的可传播铜绿假单胞菌菌株中的 1 种。67 例感染了菌株 A(15%),32 例感染了菌株 B(7%),3 例同时感染了两种菌株(0.6%)。菌株 A 被发现与利物浦流行株具有相同的遗传特征,但菌株 B 以前尚未被描述为流行株。这两种可传播菌株的新感染发病率相对较低(7.0/1000 人年;95%置信区间[CI],1.8-12.2/1000 人年)。与感染独特铜绿假单胞菌菌株的患者相比,感染利物浦流行株(菌株 A)和菌株 B 的患者肺功能下降相似(预计用力呼气量的第 1 秒下降百分比的年差异为 0.64%[95%CI,-1.52%至 2.80%]和 1.66%[95%CI,-1.00%至 4.30%])。然而,感染利物浦流行株的患者 3 年死亡率或肺移植率更高(18.6%),而非感染独特菌株的患者(8.7%)(调整后的危险比,3.26[95%CI,1.41 至 7.54];P =.01)。
一种常见的铜绿假单胞菌(利物浦流行株/菌株 A)感染了加拿大和英国的囊性纤维化患者。在加拿大囊性纤维化成年患者中,感染这种菌株与死亡或肺移植的风险增加相关。